Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 7/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19110857 | 1.00 | KCNK3 (0.43) | KCNK3SIGMAR1ENPP2IDH1ALDH1A1 | |
| SCHEMBL19110856 | 0.93 | KCNK3 (0.44) | KCNK3SIGMAR1ENPP2IDH1LMNA | |
| SCHEMBL19110853 | 0.93 | KCNK3 (0.44) | KCNK3SIGMAR1ENPP2IDH1LMNA | |
| SCHEMBL17328210 | 0.88 | KCNK3 (0.42) | KCNK3SIGMAR1ENPP2IDH1ALDH1A1 | |
| SCHEMBL17328195 | 0.88 | KCNK3 (0.42) | KCNK3SIGMAR1ENPP2IDH1ALDH1A1 | |
| SCHEMBL17317917 | 0.88 | KCNK3 (0.42) | KCNK3SIGMAR1ENPP2IDH1ALDH1A1 | |
| SCHEMBL19110698 | 0.87 | ENPP2 (0.51) | KCNK3SIGMAR1ENPP2 | |
| SCHEMBL19110727 | 0.87 | ENPP2 (0.51) | KCNK3SIGMAR1ENPP2 | |
| SCHEMBL19110741 | 0.86 | KCNK3 (0.43) | KCNK3SIGMAR1ENPP2IDH1 | |
| SCHEMBL19110738 | 0.86 | KCNK3 (0.43) | KCNK3SIGMAR1ENPP2IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197960-A1 | ATX MODULATING AGENTS | ENPP2, ATXN10, ATXN2 | KCNK3 1825/4885SIGMAR1 2505/4885ENPP2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.